Deutsche Bank AG Lowers Holdings in Humacyte, Inc. $HUMA

Deutsche Bank AG decreased its position in Humacyte, Inc. (NASDAQ:HUMA) by 11.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,757 shares of the company’s stock after selling 8,717 shares during the period. Deutsche Bank AG’s holdings in Humacyte were worth $119,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in shares of Humacyte by 40.9% in the fourth quarter. Wells Fargo & Company MN now owns 50,454 shares of the company’s stock worth $255,000 after buying an additional 14,649 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Humacyte in the 4th quarter worth approximately $377,000. First Trust Advisors LP bought a new position in Humacyte in the 4th quarter valued at approximately $1,720,000. Hsbc Holdings PLC purchased a new stake in Humacyte during the 4th quarter valued at $62,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Humacyte by 20.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company’s stock valued at $172,000 after purchasing an additional 5,801 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Brady W. Dougan sold 1,100,000 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $1.63, for a total value of $1,793,000.00. Following the completion of the sale, the director directly owned 591,685 shares of the company’s stock, valued at $964,446.55. This represents a 65.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 1,100,000 shares of the firm’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the sale, the chief executive officer owned 591,685 shares in the company, valued at $964,446.55. The trade was a 65.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,482,090 shares of company stock valued at $7,466,382. Company insiders own 5.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Benchmark decreased their target price on Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. TD Cowen reduced their price target on shares of Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, August 12th. HC Wainwright decreased their price objective on shares of Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Monday, August 11th. Finally, Barclays initiated coverage on shares of Humacyte in a research report on Wednesday. They issued an “overweight” rating and a $3.50 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Humacyte has an average rating of “Buy” and an average target price of $9.75.

Humacyte Trading Down 1.9%

Shares of HUMA stock opened at $1.55 on Monday. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. The company has a market cap of $245.47 million, a price-to-earnings ratio of -3.44 and a beta of 1.88. Humacyte, Inc. has a 1 year low of $1.15 and a 1 year high of $6.77. The firm has a fifty day moving average price of $2.14 and a 200-day moving average price of $2.25.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.94 million. As a group, equities analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.